Triptolide Shows Strong Efficacy and Safe Profile in Topical Treatment of Actinic Keratosis Lesions in UV-B-Induced Mouse Model

In 2017, a study evaluated the efficacy and safety of Triptolide (TRP) in treating actinic keratosis (AK) lesions on hairless SKH-1 mice. After inducing AK lesions with UV-B exposure for 15 weeks, the mice were treated with either 10 µg or 50 µg of TRP or a control vehicle. The treatment led to a 27% reduction in AK lesions with the 10 µg dose and an 85% reduction with the 50 µg dose, compared to a 30% increase in the control group. Histological analysis supported these findings, showing normal skin regeneration and reduced keratinocyte proliferation. The study found TRP to be safe, with no significant weight loss and only minor local inflammation, suggesting its potential as a treatment for AK lesions in humans.